| Name | Title | Contact Details |
|---|
Learn more about Cara Therapeutics, a biotechnology company focusing on pharmaceutical product development for better pruritus and pain management.
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.
Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.
R2 Technology, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.